| Therapeutic | Ipilimumab |
| Target | CTLA4 |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS |
| Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK |
| 100% seqID Fv Structure | 5tru [Fvs: HL, hl], 5xj3 [Fvs: AB, DE, GH, JK], 6jc2 [Fvs: HL], 6rp8 [Fvs: HL, hl], 7elx [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5tru [Fvs: HL, hl] |
| 100% seqID Structure | 5xj3 [Fvs: AB, DE, GH, JK] |
| 100% seqID Structure | 6jc2 [Fvs: HL] |
| 100% seqID Structure | 6rp8 [Fvs: HL, hl] |
| 100% seqID Structure | 7elx [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | Medarex UltiMAb Mouse |
| INN Year Proposed | 2005 |
| INN Year Recommended | 2006 |
| Companies Involved | Aduro BioTech, AIO Studien gGmbH, Australian and New Zealand Urogenital and Prostate Cancer Group, Bavarian Nordic, Big Ten Cancer Research Consortium, BioGene Pharmaceutical, Bristol-Myers Squibb, Canadian Cancer Trials Group, Dana-Farber Cancer Institute, European Thoracic Oncology Platform, Grupo Espanol Multidisciplinar de Melanoma, Icahn School of Medicine at Mount Sinai, Intergroupe Francophone de Cancerologie Thoracique, Ludwig Institute for Cancer Research, Massachusetts General Hospital, Medarex, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), National University Hospital (Singapore), Northwestern University, Olivia Newton-John Cancer Research Institute, OncoTherapy Science, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University College London, University of California at San Francisco, University of Texas M. D. Anderson Cancer Center |
| Conditions Approved | Malignant melanoma, Renal cell carcinoma |
| Conditions Active | Colorectal cancer, Non-small cell lung cancer, Gastric cancer, Glioblastoma, Head and neck cancer, Mesothelioma, Oesophageal cancer, Prostate cancer, Small cell lung cancer, Urogenital cancer, Adrenocortical carcinoma, Breast cancer, CNS cancer, Gastrointestinal cancer, Genitourinary disorders, Gynaecological cancer, Liver metastases, Meningeal carcinomatosis, Myelodysplastic syndromes, Neuroendocrine tumours, Ovarian cancer, Pancreatic cancer, Penile cancer, Solid tumours, Thyroid cancer, Uveal melanoma, Diffuse large B cell lymphoma, Liver cancer, Lung cancer, Glioma |
| Conditions Discontinued | HIV infections, Lymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
